Oral treatments for fungal infections of the skin of the foot

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 3, 2012, Pages

  Bell Syer, Sally EM ^a   Khan, Sameena M ^a   Torgerson, David J ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT;

CHRONIC DISEASE; HUMAN; META ANALYSIS; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TINEA PEDIS;

ADMINISTRATION, ORAL; ANTIFUNGAL AGENTS; CHRONIC DISEASE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TINEA PEDIS;

EID: 84871898272     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003584.pub2     Document Type: Article

References (68)

1. De Keyser P, De Backer M, Massart DL, Westerlinck KJ. Two week oral treatment of tinea pedis, comparing terbinafine (250mg/day) with itraconazole (100mg/day): a double blind multicentre study. British Journal of Dermatology 1994;130(Suppl 43):22-5.
2. Difonzo EM, Papini M, Cilli P, Calandra P, Panconesi E. A double blind study comparison of itraconazole and fluconazole in tinea pedis and tinea manuum. Journal of the European Academy of Dermatology & Venereology 1995;4(2):148-52.
3. Fischbein A, Haneke E, Lacner K. Comparative evaluation of oral fluconazole and oral ketoconazole in the treatment of fungal infections of the skin. International Journal of Dermatology 1992;31(Suppl 2):12-6.
4. Hay RJ, McGregor JM, Wuite J, Ryattk KS, Ziegler C, Clayton YM. A comparison of 2 weeks terbinafine 250mg/day with 4 weeks of itraconazole 100mg/day in plantar - type tinea pedis. British Journal of Dermatology 1995;132 132:604-8.
5. Hoharitanon S, Chaichalotornkul J, Sindhupak W. A comparison of the efficacy between two Itraconazole generic products and the innovative Itraconazole in the treatment of tinea pedis. Journal of the Medical Association of Thailand 2005;88(Suppl 4):s167-72.
6. Kim JH, Yoon KB. Single blind randomised study of terbinafine vs itraconazole in tinea pedis (two weeks vs four weeks). Terbinafine in the Treatment of Superficial Fungal Infections. Proceedings of the Asia-Pacific Symposium on Lamisil, Series: International Congress and Symposium 205. London: Royal Society of Medicine Services, 1993; Vol. 205:17-20.
7. Nozickova M, Koudelkova V, Kulikova Z, Malina L, Urbanowski S, Silny W. A comparison of the efficacy of oral fluconazole, 150 mg/week versus 50 mg/day, in the treatment of tinea corporis, tinea cruris, tinea pedis and cutaneous candidosis. International Journal of Dermatology 1998;37(9):703-5.
8. Roberts DT, Cox NH, Gentles JC, Babu KK. Comparison of ketoconazole and griseofulvin in the treatment of tinea pedis. Journal of Medical and Veterinary Mycology 1987;25(5):347-50.
9. Savin R. Successful treatment of chronic tinea pedis (moccasin type) with terbinafine (Lamisil). Clinical Experimental Dermatology 1989;14(2):116-9.
10. Savin RC, Zaias N. Treatment of chronic moccasin type tinea pedis with terbinafine: a double-blind, placebo-controlled trial. Journal of American Academy of Dermatology 1990;23(4 Pt 2):804-7.
11. Savin RC. Oral terbinafine versus griseofulvin in the treatment of moccasin-type tinea pedis. Journal of American Academy of Dermatology 1990;23(4 Pt 2):807-9.
12. Savin RC. Terbinafine (Lamisil) versus griseofulvin in moccasin type tinea pedis. Journal of Dermatological Treatment 1990;1(Suppl 2):43-6.
13. Smith S, Houpt K, Rich P, LaMarca A, Weinberg JM, Alferez TS, et al. Short-duration oral Terbinafine for the treatment of tinea pedis in HIV-Positive patients. Cutis 2001;68(1 Suppl):30-9.
14. Svejgaard E, Avnstorp C, Wanscher B, Nilsson J, Heremans A. Efficacy and safety of short-term itraconazole in tinea pedis: a double-blind, randomized, placebo-controlled trial. Dermatology 1998;197(4):368-72.
15. Voravutinon V. Double blind comparative study of the efficacy and tolerability of terbinafine with itraconazole in patients with tinea pedis. Terbinafine in the Treatment of Superficial Fungal Infections. Proceedings of the Asia-Pacific Symposium on Lamisil, Series: International Congress and Symposium 205. London: Royal Society of Medicine Services, 1993; Vol. 205:11-6.
16. Widyanto, Budimulja U, Kuswadji, Kusmarinah B. A randomised double blind comparative study of terbinafine vs griseofulvin in tinea pedis. Terbinafine in the Treatment of Superficial Fungal Infections. Proceedings of the Asia-Pacific Symposium on Lamisil, Series: International Congress and Symposium 205. London: Royal Society of Medicine Services, 1993; Vol. 205:21-4.
17. Yamauchi K, Hiruma M, Yamazaki N, Wakabayashi H, Kuwata H, Teraguchi S, et al. Oral administration of bovine lactoferrin for treatment of tinea pedis. A placebo-controlled, double blind study. Mycoses 2000;43(5):197-202.
18. Baldari U, Righini MG, Raccagni AA, Ghittoni L, Biggio P, Pau M, et al. Comparative double blind, double dummy study on the efficacy and safety of fluconazole 100mg/day versus terbinafine 250mg/day in the treatment of dermatomycoses. Giornale Italiano di Dermatologia e Venereologia 2000;135(2):229-235.
19. Barnetson RS, Marley J, Bullen M, Brookman S, Cowen P, Ellis D, et al. Comparison of one week of oral terbinafine (250mg/day) with four weeks of treatment with clotrimazole 1% cream in interdigital tinea pedis. British Journal of Dermatology 1998;139(4):675-8.
20. Bortolussi R, Moore DL, Robinson JL, Rousseau-Harsany E, Samson LM, MacDonald NE, et al. Antifungal agents for common paediatric infections [Les antifongiques dans le traitement des infections pediatriques courantes]. Paediatric & Child Health 2007;12(10):875-883.
21. Bortolussi R, Moore DL, Robinson JL, Rousseau-Harsany E, Samson LM, MacDonald NE, et al. Antifungal agents for common paediatric infections. Canadian Journal of Infectious Diseases & Medical Microbiology 2008;19(1):15-18.
22. Brugmans J, Van Cutsem J. A three-stage clinical evaluation of etonam (R10 100) in the treatment of chronic athlete's foot. Dermatologica 1969;138(5):403-17.
23. Decroix J, Ausma J, Cauwenbergh G, Borgers M, Wouters L. The efficacy of oral treatment with pramiconazole in tinea pedis and tinea cruris/corporis: two exploratory phase IIa trials. British Journal of Dermatology 2008;158(4):854-856.
24. Degreef H, Marian K, De Veyler H, Duprez K, Borghys A, Verhoeve L. Itraconazole in the treatment of dermatophytoses: a comparison of two daily dosages. Reviews of Infectious Diseases 1987;9(Suppl 1):S104-8.
25. Del Palacio A, Van Cutsem J, Lopez S, Roiz MP, Cuetaria MS, Iglesias L, et al. Double blind randomised comparative study on tinea manuum and tinea pedis treated with itraconazole and griseofulvin [Estudio doble ciego aleatorio comparativo con itraconzol y griseofulvina en tinea manuum y tinea pedis]. Actas Dermo-Sifiliograficas 1993;84(1-2):45-53.
26. Gupta AK, Nolting S, de Prost Y, Delescluse J, Degreef H, Theissen U, et al. The use of itraconazole to treat cutaneous fungal infections in children. Dermatology 1999;199(3):248-252.
27. Hay RJ, Logan RA, Moore MK, Midgely G, Clayton YM. A comparative study of terbinafine versus griseofulvin in 'dry - type' dermatophyte infections. Journal of American Academy of Dermatology 1991;24(2 Pt 1):243-6.
28. Humphreys F. Terbinafine. Journal of Drug Evaluation 2004;2(5):133-155.
29. Jolly HW, Daily AD, Rex IH, Krupp I, Tromovitch TA, Stegman SJ, et al. A multicentre double-blind evaluation of ketoconazole in the treatment of dermatomycoses. Cutis 1983;31(2):208-10.
30. Lachapelle JM, De Doncker P, Tennstedt D, Cauwenbergh G, Janssen PA. Itraconazole compared with griseofulvin in the treatment of tinea corporis/cruris and tinea pedis/manus: an interpretation of the clinical results of all completed double-blind studies with respect to the pharmacokinetic profile. Dermatology 1992;184(1):45-50.
31. Legendre R, Steltz M. A multi-center double blind comparison of ketoconazole and griseofulvin in the treatment of infections due to dermatophytes. Reviews of Infectious Diseases 1980;2(4):586-91.
32. Lynfield YL, Littman ML, Feingold LE. Treatment of tinea pedis with micronized griseofulvin and tolnaftate. Cutis 1974;13(3):460-2.
33. Markova T. Clinical inquiries: What is the most effective treatment for tinea pedis (athlete's foot)?. Journal of Family Practice 2002;51(1):21.
34. Russell B, Frain-Bell W, Stevenson CJ, Riddell RW, Djavahiszwili N, Morrison SL. Chronic ringworm infection of the skin and nails treated with griseofulvin. Report of a therapeutic trial. Lancet 1960;1(7135):1141-7.
35. Schuller J, Remme JJ, Rampen FH, Van Neer FC. Itraconazole in the treatment of tinea pedis and tinea manuum: comparison of two treatment schedules. Mycoses 1998;41(11-12):515-20.
36. Stengel F, Robles-Soto M, Galimberti R, Suchil P. Fluconazole versus ketoconazole in the treatment of dermatophytoses and cutaneous candidiasis. International Journal of Dermatology 1994;33(10):726-9.
37. Tausch I, Decroix J, Gwiezdzinski Z, Urbanowski S, Baran E, Ziarkiewicz M, et al. Short-term itraconazole versus terbinafine in the treatment of tinea pedis or manus. International Journal of Dermatology 1998;37(2):140-2.
38. Van Hecke E, Van Cutsem J. Double-blind comparison of itraconazole with griseofulvin in the treatment of tinea pedis and tinea manuum. Mycoses 1988;31(12):641-9.
39. White JE, Perkins P, Evans EGV. Successful treatment of chronic tinea pedis and tinea manuum with Lamisil (terbinafine). British Journal of Dermatology 1990;123(Suppl 37):30.
40. White JE, Perkins PJ, Evans EG. Successful 2-week treatment with terbinafine (Lamisil) for moccasin tinea pedis and tinea manuum. British Journal of Dermatology 1991;125(3):260-2.
41. Wishart JM. A double blind study of itraconazole vs griseofulvin in patients with tinea pedis and tinea manus. New Zealand Medical Journal 1994;107(975):126-8.
42. Won YH, Kim SJ, Lee HW, Chun IK. Clinical comparative study of terbinafine and itraconazole in the treatment of tinea pedis. Terbinafine in the Treatment of Superficial Fungal Infections. Proceedings of the Asia-Pacific Symposium on Lamisil, Series: International Congress and Symposium 205. London: Royal Society of Medicine Services, 1993; Vol. 205:7-10.
43. Yao ZY, Liu YS, Wang C, Pan DH, Zheng ZC, Zhang XY, et al. Clinical observation on the efficacy of 1 week and 2 weeks treatment of itraconazole in tinea pedis. Chinese Journal of Dermatology 1999;32(5):360-1.
44. Decroix J. Tinea pedis (mocassin-type) treated with itraconazole. International Journal of Dermatology 1995;34(2):122-124.
45. NCT00509275. A Study to Evaluate Efficacy and Safety of Three W0027 Regimens in the Treatment of Moccasin Type Tinea Pedis (MTTP). clinicaltrials.gov/ct2/show/NCT00509275.
46. Alderova L, Baroskova A, Faldyna M. Lactoferrin: A review. Veterinari Medicina 2008;53(9):457-68.
47. Auger P, Marquis G, Joly J, Attye A. Epidemiology of tinea pedis in marathon runners: prevalence of occult athlete’s foot. Mycoses 1993;36(1-2):35-41.
48. Begg CB, Berlin JA. Publication bias and dissemination of clinical research. Journal of the National Cancer Institute 1989;81(2):107-15.
49. Brautigam M, Nolting S, Schopf G, Weidinger G. Randomised double blind comparison of terbinafine and itraconazole for the treatment of toenail tinea infection. Seventh Lamisil German Onychomycosis Study Group. BMJ 1995;311(7010):919-22.
50. Brooks KE, Bender JF. Tinea pedis diagnosis and treatment. Clinics in Podiatric Medicine & Surgery 1996;13(1):31-46.
51. Catterall MD. The incidence and epidemiology of tinea pedis in the crew of a nuclear submarine. Journal of the Royal Naval Medical Service 1975;61(2):92-7.
52. Detandt M, Nolard N. Fungal contamination of the floors of swimming pools, particularly subtropical swimming paradises. Mycoses 1995;38(11-12):509-13.
53. Elewski BE. Diagnostic techniques for confirming onychomycosis. Journal of the American Academy of Dermatology 1996;35(3 Pt 2):S6-9.
54. English MP, Gibson MD. Studies in the epidemiology of tinea pedis I. Tinea pedis in school children. BMJ 1959;1(5135):1442-6.
55. English MP, Gibson MD, Warin RP. Studies in the epidemiology of tinea pedis: VI Tinea pedis in a boarding school. BMJ 1961;1:1083-5.
56. Gentles JC, Holmes JG. Foot ringworm in coal-miners. British Journal of Industrial Medicine 1957;14(1):22-9.
57. Gentles JC, Evans EG. Foot infections in swimming baths. BMJ 1973;3(5874):260–2.
58. Gupta AK, Sauder DN, Shear NH. Antifungal agents: An overview. Part I. Journal of American Academy of Dermatology 1994;30(5 Pt 1):677-98.
59. Gupta AK, Sauder MD, Shear NH. Antifungal agents: An overview. Part II. Journal of American Academy of Dermatology 1994;30(6):911-33.
60. Hart R, Bell-Syer SE, Crawford F, Torgerson DJ, Young P, Russell I. Systematic review of topical treatment for fungal infections of the skin and nails of the feet. BMJ 1999;319(7202):79-82.
61. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
62. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011. Available from www.cochrane-handbook.org.
63. Jones HE. Ketoconazole. Archives Dermatology 1982;118(4):217-9.
64. Merlin K, Kilkenny M, Plunkett A, Marks R. The prevalence of common skin conditions in Australian school students: 4 Tinea pedis. British J Dermatology 1999;140(5):897-901.
65. MIMS. Monthly Index of Medical Specialities. London: Haymarket Medical Ltd, 2000.
66. Roseeuw D. Achilles foot screening project: preliminary results of patients screened by dermatologists. Journal of the European Academy of Dermatology & Venereology 1999;12(Suppl 1):S6-9.
67. Wakabayashi H, Uchida K, Yamauchi K, Teraguchi S, Hayasawa H, Yamaguchi H. Lactoferrin given in food facilitates dermatophytosis cure in guinea pig models. Journal of Antimicrobial Chemotherapy 2000;46(4):595-602.
68. Bell-Syer SEM, Hart R, Crawford F, Torgerson DJ, TyrrellW, Russell I. Oral treatments for fungal infections of the skin of the foot. Cochrane Database of Systematic Reviews 2002, Issue 2. [DOI: 10.1002/14651858.CD003584]